Department of Brain Sciences, Imperial College London, London W12 0NN, UK.
UK Dementia Research Institute at Imperial College London, London W12 0NN, UK.
Sci Transl Med. 2022 Aug 17;14(658):eabk1051. doi: 10.1126/scitranslmed.abk1051.
Cell stress and impaired oxidative phosphorylation are central to mechanisms of synaptic loss and neurodegeneration in the cellular pathology of Alzheimer's disease (AD). In this study, we quantified the in vivo expression of the endoplasmic reticulum stress marker, sigma 1 receptor (S1R), using [C]SA4503 positron emission tomography (PET), the mitochondrial complex I (MC1) with [F]BCPP-EF, and the presynaptic vesicular protein SV2A with [C]UCB-J in 12 patients with early AD and in 16 cognitively normal controls. We integrated these molecular measures with assessments of regional brain volumes and cerebral blood flow (CBF) measured with magnetic resonance imaging arterial spin labeling. Eight patients with AD were followed longitudinally to estimate the rate of change of the physiological and structural pathology markers with disease progression. The patients showed widespread increases in S1R (≤ 27%) and regional reduction in MC1 (≥ -28%) and SV2A (≥ -25%) radioligand binding, brain volume (≥ -23%), and CBF (≥ -26%). [F]BCPP-EF PET MC1 binding (≥ -12%) and brain volumes (≥ -5%) showed progressive reductions over 12 to 18 months, suggesting that they both could be used as pharmacodynamic indicators in early-stage therapeutics trials. Associations of reduced MC1 and SV2A and increased S1R radioligand binding with reduced cognitive performance in AD, although exploratory, suggested a loss of metabolic functional reserve with disease. Our study thus provides in vivo evidence for widespread, clinically relevant cellular stress and bioenergetic abnormalities in early AD.
细胞应激和氧化磷酸化受损是阿尔茨海默病(AD)细胞病理学中突触丧失和神经退行性变的机制核心。在这项研究中,我们使用[C]SA4503 正电子发射断层扫描(PET)、线粒体复合物 I(MC1)与[F]BCPP-EF 以及突触小泡蛋白 SV2A 的[C]UCB-J 定量测定了内质网应激标志物西格玛 1 受体(S1R)在 12 名早期 AD 患者和 16 名认知正常对照者体内的表达。我们将这些分子测量结果与磁共振成像动脉自旋标记测量的区域脑容量和脑血流(CBF)评估相结合。8 名 AD 患者进行了纵向随访,以估计随着疾病进展,生理和结构病理学标志物的变化率。患者表现出 S1R(≤27%)广泛增加,MC1(≥-28%)和 SV2A(≥-25%)放射性配体结合、脑容量(≥-23%)和 CBF(≥-26%)区域性减少。[F]BCPP-EF PET MC1 结合(≥-12%)和脑容量(≥-5%)在 12 至 18 个月内逐渐减少,这表明它们都可以用作早期治疗试验中的药效学指标。尽管是探索性的,但 AD 中 MC1 和 SV2A 减少以及 S1R 放射性配体结合增加与认知能力下降的相关性表明,随着疾病的发展,代谢功能储备减少。因此,我们的研究为早期 AD 中广泛存在的、具有临床相关性的细胞应激和生物能异常提供了体内证据。